ArticleJournal of immunology (Baltimore, Md. : 1950)2013
CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 103 citations in OpenAlex.
- The CD160-HVEM axis at the crossroads of tolerance and immunity: lessons from cancer for autoimmunity and transplantation.Frontiers in immunology · 2026Review
- CD160 mediated NK cell activation shapes host defense against acuteFrontiers in immunology · 2026Article
- MutantFrontiers in immunology · 2026Article
- Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective.Clinical and experimental medicine · 2025Review
- Splenic TNF-α signaling potentiates the innate-to-adaptive transition of antiviral NK cells.Immunity · 2025Article
- TNF superfamily molecules in atherosclerosis: mechanistic insights and therapeutic translation.Frontiers in immunology · 2025Review
- Virus-specific Th17 Cells Are Induced by Human Cytomegalovirus after Renal Transplantation.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Protein Identification for Stroke Progression via Mendelian Randomization in Million Veteran Program and UK Biobank.Stroke · 2024Article
- Antimicrobial activity of NK cells to Trypanosoma cruzi infected human primary Keratinocytes.PLoS neglected tropical diseases · 2024Article
- Effect ofInternational journal of molecular sciences · 2024Article
- Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation.Nature communications · 2023Article
- Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.Molecular cancer · 2023Review
- BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia.Cancer immunology, immunotherapy : CII · 2023Article
- Liver Transcriptome Analysis Reveals Energy Regulation and Functional Impairment of Onychostoma sima During Starvation.Marine biotechnology (New York, N.Y.) · 2023Article
- Landscape of costimulatory molecule signature in breast cancer and its prognostic significance.Annals of translational medicine · 2023Article
- Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1Frontiers in immunology · 2023Article
- Transcriptional reprogramming of natural killer cells by vaccinia virus shows both distinct and conserved features with mCMV.Frontiers in immunology · 2023Article
- The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.Cancer immunology, immunotherapy : CII · 2022Article
- A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma.Journal of translational medicine · 2022Article
- Realigning the LIGHT signaling network to control dysregulated inflammation.The Journal of experimental medicine · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Lymphocyte activation is regulated by costimulatory and inhibitory receptors, of which both B and T lymphocyte attenuator (BTLA) and CD160 engage herpesvirus entry mediator (HVEM). Notably, it remains unclear how HVEM functions with each of its ligands during immune responses. In this study, we show that HVEM specifically activates CD160 on effector NK cells challenged with virus-infected cells. Human CD56(dim) NK cells were costimulated specifically by HVEM but not by other receptors that share the HVEM ligands LIGHT, Lymphotoxin-α, or BTLA. HVEM enhanced human NK cell activation by type I IFN and IL-2, resulting in increased IFN-γ and TNF-α secretion, and tumor cell-expressed HVEM activated CD160 in a human NK cell line, causing rapid hyperphosphorylation of serine kinases ERK1/2 and AKT and enhanced cytolysis of target cells. In contrast, HVEM activation of BTLA reduced cytolysis of target cells. Together, our results demonstrate that HVEM functions as a regulator of immune function that activates NK cells via CD160 and limits lymphocyte-induced inflammation via association with BTLA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.